Bajjalieh SM, Peterson K, Shinghal R, Scheller RH: SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science. 1992, 257 (5074): 1271-1273. 10.1126/science.1519064.
Article
CAS
PubMed
Google Scholar
Bindra PS, Knowles R, Buckley KM: Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells. Gene. 1993, 137 (2): 299-302. 10.1016/0378-1119(93)90024-W.
Article
CAS
PubMed
Google Scholar
Tao-Cheng JH: Ultrastructural localization of active zone and synaptic vesicle proteins in a preassembled multi-vesicle transport aggregate. Neuroscience. 2007, 150 (3): 575-584. 10.1016/j.neuroscience.2007.09.031.
Article
PubMed Central
CAS
PubMed
Google Scholar
Feany MB, Lee S, Edwards RH, Buckley KM: The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell. 1992, 70 (5): 861-867. 10.1016/0092-8674(92)90319-8.
Article
CAS
PubMed
Google Scholar
Janz R, Sudhof TC: SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience. 1999, 94 (4): 1279-1290. 10.1016/S0306-4522(99)00370-X.
Article
CAS
PubMed
Google Scholar
Buckley K, Kelly RB: Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol. 1985, 100 (4): 1284-1294. 10.1083/jcb.100.4.1284.
Article
CAS
PubMed
Google Scholar
Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH: Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994, 14 (9): 5223-5235.
CAS
PubMed
Google Scholar
Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER: SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006, 312 (5773): 592-596. 10.1126/science.1123654.
Article
CAS
PubMed
Google Scholar
Bajjalieh SM, Peterson K, Linial M, Scheller RH: Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A. 1993, 90 (6): 2150-2154. 10.1073/pnas.90.6.2150.
Article
PubMed Central
CAS
PubMed
Google Scholar
Miyauchi N, Saito A, Karasawa T, Harita Y, Suzuki K, Koike H, Han GD, Shimizu F, Kawachi H: Synaptic vesicle protein 2B is expressed in podocyte, and its expression is altered in proteinuric glomeruli. J Am Soc Nephrol. 2006, 17 (10): 2748-2759. 10.1681/ASN.2005121293.
Article
CAS
PubMed
Google Scholar
Wang MM, Janz R, Belizaire R, Frishman LJ, Sherry DM: Differential distribution and developmental expression of synaptic vesicle protein 2 isoforms in the mouse retina. J Comp Neurol. 2003, 460 (1): 106-122. 10.1002/cne.10636.
Article
CAS
PubMed
Google Scholar
Hayashi M, Yamamoto A, Yatsushiro S, Yamada H, Futai M, Yamaguchi A, Moriyama Y: Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. J Neurochem. 1998, 71 (1): 356-365.
Article
CAS
PubMed
Google Scholar
Iezzi M, Theander S, Janz R, Loze C, Wollheim CB: SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J Cell Sci. 2005, 118 (Pt 23): 5647-5660.
Article
CAS
PubMed
Google Scholar
Dardou D, Dassesse D, Cuvelier L, Deprez T, De Ryck M, Schiffmann SN: Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res. 2011, 1367: 130-145.
Article
CAS
PubMed
Google Scholar
Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER: Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell. 2008, 19 (12): 5226-5237. 10.1091/mbc.E08-07-0765.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T: The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580 (8): 2011-2014. 10.1016/j.febslet.2006.02.074.
Article
CAS
PubMed
Google Scholar
Janz R, Goda Y, Geppert M, Missler M, Sudhof TC: SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 1999, 24 (4): 1003-1016. 10.1016/S0896-6273(00)81046-6.
Article
CAS
PubMed
Google Scholar
Chang WP, Sudhof TC: SV2 renders primed synaptic vesicles competent for Ca2+ − induced exocytosis. J Neurosci. 2009, 29 (4): 883-897. 10.1523/JNEUROSCI.4521-08.2009.
Article
PubMed Central
CAS
PubMed
Google Scholar
Venkatesan K, Alix P, Marquet A, Doupagne M, Niespodziany I, Rogister B, Seutin V: Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice. Journal of neuroscience research. 2012, 90 (12): 2317-2327. 10.1002/jnr.23111.
Article
CAS
PubMed
Google Scholar
Custer KL, Austin NS, Sullivan JM, Bajjalieh SM: Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci. 2006, 26 (4): 1303-1313. 10.1523/JNEUROSCI.2699-05.2006.
Article
CAS
PubMed
Google Scholar
Xu T, Bajjalieh SM: SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001, 3 (8): 691-698. 10.1038/35087000.
Article
CAS
PubMed
Google Scholar
Schivell AE, Batchelor RH, Bajjalieh SM: Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996, 271 (44): 27770-27775. 10.1074/jbc.271.44.27770.
Article
CAS
PubMed
Google Scholar
Pyle RA, Schivell AE, Hidaka H, Bajjalieh SM: Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem. 2000, 275 (22): 17195-17200. 10.1074/jbc.M000674200.
Article
CAS
PubMed
Google Scholar
Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM: Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci. 2010, 30 (16): 5569-5578. 10.1523/JNEUROSCI.4781-09.2010.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wan QF, Vila A, Zhou ZY, Heidelberger R: Synaptic vesicle dynamics in mouse rod bipolar cells. Vis Neurosci. 2008, 25 (4): 523-533.
Article
PubMed Central
PubMed
Google Scholar
Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R: SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron. 2010, 66 (6): 884-895. 10.1016/j.neuron.2010.05.010.
Article
PubMed Central
CAS
PubMed
Google Scholar
Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM: Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA. 1999, 96 (26): 15268-15273. 10.1073/pnas.96.26.15268.
Article
PubMed Central
CAS
PubMed
Google Scholar
De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007, 13 (1): 43-56. 10.1111/j.1527-3458.2007.00004.x.
Article
CAS
PubMed
Google Scholar
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004, 101 (26): 9861-9866. 10.1073/pnas.0308208101.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O’Rourke D, Doherty CP, Shianna KV, et al: No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 2009, 83 (1): 44-51. 10.1016/j.eplepsyres.2008.09.003.
Article
CAS
PubMed
Google Scholar
Feng G, Xiao F, Lu Y, Huang Z, Yuan J, Xiao Z, Xi Z, Wang X: Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy. J Mol Neurosci. 2009, 39 (3): 354-359. 10.1007/s12031-009-9288-2.
Article
CAS
PubMed
Google Scholar
Crèvecœur J, Kaminski RM, Rogister B, Foerch P, Vandenplas C, Neveux M, Mazzuferi M, Kroonen J, Poulet C, Martin D, Sadzot B, Rikir E, Klitgaard H, Moonen G, Deprez M: Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis. Neuropathol Appl Neurobiol. 2013, 10.1111/nan.12054. In Press. [Epub ahead of print]
Google Scholar
Klitgaard H, Verdu P: Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2007, 2 (11): 1537-1545. 10.1517/17460441.2.11.1537.
Article
CAS
PubMed
Google Scholar
Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, et al: Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004, 47 (3): 530-549. 10.1021/jm030913e.
Article
CAS
PubMed
Google Scholar
Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H: Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008, 154 (8): 1662-1671.
Article
PubMed Central
CAS
PubMed
Google Scholar
von Rosenstiel P: Brivaracetam (UCB 34714). Neurotherapeutics. 2007, 4 (1): 84-87. 10.1016/j.nurt.2006.11.004.
Article
CAS
PubMed
Google Scholar
Taveggia C, Feltri ML, Wrabetz L: Signals to promote myelin formation and repair. Nat Rev Neurol. 2010, 6 (5): 276-287. 10.1038/nrneurol.2010.37.
Article
PubMed Central
PubMed
Google Scholar
Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P: Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003, 478 (1): 1-9. 10.1016/j.ejphar.2003.08.032.
Article
CAS
PubMed
Google Scholar
Fuks B, Gillard M, Michel P, Lynch B, Vertongen P, Leprince P, Klitgaard H, Chatelain P: Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol. 2003, 478 (1): 11-19. 10.1016/j.ejphar.2003.08.033.
Article
CAS
PubMed
Google Scholar
Represa A, Ben-Ari Y: Trophic actions of GABA on neuronal development. Trends Neurosci. 2005, 28 (6): 278-283. 10.1016/j.tins.2005.03.010.
Article
CAS
PubMed
Google Scholar
Harris KM, Teyler TJ: Developmental onset of long-term potentiation in area CA1 of the rat hippocampus. J Physiol. 1984, 346: 27-48.
Article
PubMed Central
CAS
PubMed
Google Scholar
de Groot M, Aronica E, Heimans JJ, Reijneveld JC: Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology. 2011, 77 (6): 532-539. 10.1212/WNL.0b013e318228c110.
Article
CAS
PubMed
Google Scholar
Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H: SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 2008, 54 (4): 715-720. 10.1016/j.neuropharm.2007.11.021.
Article
CAS
PubMed
Google Scholar
Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, Dassesse D, Matagne A, Klitgaard H: Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia. 2009, 50 (7): 1729-1740. 10.1111/j.1528-1167.2009.02089.x.
Article
CAS
PubMed
Google Scholar
Gillard M, Fuks B, Leclercq K, Matagne A: Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011, 664 (1–3): 36-44.
Article
CAS
PubMed
Google Scholar
de Kok JB, Ruers TJ, van Muijen GN, van Bokhoven A, Willems HL, Swinkels DW: Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem. 2000, 46 (3): 313-318.
CAS
PubMed
Google Scholar